August 14, 2026: Washington, DC – Today, the National Consumers League (NCL) is proud to celebrate the 91st anniversary of the Social Security Act. This landmark achievement helped establish a stronger economic foundation for millions of American families.
August 13, 2026: In casual speech, geologic time is a way of describing an excessively long, painfully slow process of change. It is appropriate to describe how long it has taken the Food and Drug Administration (FDA) to issue a proposed rule to strengthen the agency’s oversight of food ingredients determined to be “Generally Recognized as Safe” (GRAS).
June 17, 2026: Chronic diseases, like diabetes, heart disease, hypertension, and certain cancers, get a lot of attention from policymakers for obvious reasons. Collectively, these diseases affect more than 75 percent of American adults and drive approximately 90 percent of the nation’s healthcare costs.
May 21, 2026: Washington DC – Consumer Advocates Urge Senate Leadership to Bring S. 281 to the Floor, Aligning with the 87% of Voters Demanding Strict Protections Against Fraud, Junk Fees, and Speculative Ticketing. With comprehensive new public opinion survey data showing near-unanimous American consensus in favor of live event ticketing reform, the National Consumers League (NCL) today called on Senate leadership to immediately schedule a floor vote on S. 281, the Transparency In Charges for Key Events Ticketing Act (the TICKET Act).
May 21, 2026: May 22, 2025 – the date set by the Food and Drug Administration for the end of sales of mass-marketed compounded GLP-1 weight-loss drugs – is a barometer of how far we have come in regulating untested, unapproved GLP-1 products and how far we still need to go.
May 20, 2026: I was living in Boston in 1987 when a thunderclap of a headline hit the front page of the Boston Globe: Barney Frank was about to be outed over a relationship with a man he had hired as a “massage therapist,” and he decided to get ahead of the story himself.
The work of the National Consumers League is making a difference in people’s lives across the country. Meet some of the consumers touched by our programs.
Read about NCL’s impact
Paige, 55, a Nashville wife and mother of two, answered an employment ad for secret shoppers. Before sending payment to the scammers, she reached out to NCL.
Read about NCL’s impact
A grease fire flared up in Decklan’s kitchen. As his family scrambled and panicked, fearing that the whole house might erupt in flames, Decklan remained calm. He hurried over to the pantry, grabbed some baking soda, and dumped it on the fire quickly extinguishing the blaze.
Read about NCL’s impact
Cincinnati resident Charles, 45, lost his computer business — and health insurance— during a time of economic downturn. A diabetic, Charles was now unable to afford his medication. He stopped taking it which made him seriously ill and put his life at risk.
Read about NCL’s impact
Jeremy is a fast-food worker who has been employed at a number of Chipotle restaurants in New York City. When he was just 20 years old, he took part in an NCL research project that revealed that management practices within the fast food chain were putting workers—and food safety for customers—at risk.
Read about NCL’s impact
By Sally Greenberg, NCL Executive Director
While the COVID-19 pandemic has led to hardship for all Americans, it is clear that people of color have been disproportionately burdened. Across the health care continuum, addressing this disparity has become part of the broader conversation about the history of systemic racism and the underlying social determinants of health that negatively affect the mental, physical, and economic health of individuals and entire communities.
The pandemic has underscored persistent health disparities, and there is growing recognition that representation in research and clinical trials can have a profound impact on health outcomes. A lack of representation from racially and ethnically diverse groups in research and clinical trials have typically led to gaps in data, missing the opportunity to assess the full impact of various treatments and drugs across a range of populations. The collection and use of real-world research and data to inform the potential use, risks, and benefits of medical products and treatments can ultimately lead to better health outcomes, particularly for those who have been underrepresented in the past.
Existing efforts to improve inclusion
Efforts to expand diversity and representation in medical research are underway in Congress. Policymakers are encouraging the incorporation of Real World Evidence (RWE) in drug development through the recent Cures 2.0 draft legislation released by Reps. Diana Degette (D-CO-1) and Fred Upton (D-MI-6). While the status quo limits us from effectively reaching underserved populations, the proposed legislation would allow studies that include RWE for some drugs after they have been approved. At the heart of this issue is a growing appreciation that the same therapy can affect different populations in different ways, which is why Cures 2.0 supports collecting data that more accurately reflects the unique experiences and needs of patients across diverse populations.
Recognizing the potential for RWE in maternal health
The lack of representative research in the field of maternal health is undeniable, and its implications are staggering. The dismal state of maternal care in the United States reflects how our health care system has failed women of color, including by not adequately studying treatment options to prevent maternal morbidity and mortality. The need for RWE is clear when you consider the persistent disparities in health outcomes that plague minority communities.
Preterm birth and its disproportionate impact on women of color is a stark illustration of the need to make progress on representative research in maternal health. Preterm birth is the second-largest contributor to infant death in America today. Despite the tremendous physical, emotional, and financial toll that preterm birth continues to take on our country — disproportionately so on women and families of color — not enough therapeutic tools currently exist to prevent it.
Today, “17P,” the only FDA-approved treatment to help reduce the likelihood of spontaneous, recurrent preterm birth in the United States is at-risk of being withdrawn from the market in all its forms, including the branded product and five generic versions. Unfortunately there is conflicting evidence from two different clinical trials, one representative of a diverse U.S. population and another studied in a largely white population in Europe. It’s not a straightforward comparison. If 17P is withdrawn, the women most affected by preterm birth, predominantly women of color, would be left without an FDA-approved treatment option.
The FDA is considering the path forward, including additional data collection through leveraging RWE from past patient use. The success of the first (approval) trial for 17P in the impacted communities signals the importance of RWE. Continued access to 17P is, at its core, a matter of health equity. Black women must not yet again be left vulnerable to a system that historically has overlooked them.
